Growth Hormone Axis research peptides leave later health risks uncertain

The developers aimed to increase hormone from your own gland

The developers wanted more growth hormone released by your body. Your pituitary gland sits just under your brain and makes that hormone. Growth hormone also prompts insulin-like growth factor, the liver's hormone that helps cells grow. Those higher readings don't necessarily mean you'll feel better.

The gland and liver work together; that's the growth hormone axis. Peptides contain linked amino acids, the tiny parts in proteins. Tesamorelin and sermorelin copy a hormone that prompts your gland. The action copied by ipamorelin comes from your hunger hormone.

The drugs prompt different receptors, which are proteins responding to hormones. CJC-1295 / ipamorelin would use both kinds of receptor. The CJC partner copies the hormone that prompts gland release; ipamorelin prompts the hunger hormone's receptor. Working together doesn't prove either drug makes you healthier.

The evidence ranges from patient trials to animal and cell tests. Your concern may never have been tested in those studies. More hormone measured in your blood isn't a health gain. Check the patients' health gains, illnesses and reasons for stopping.

Later illnesses can fall beyond the end of a trial

A trial can only count illness while follow-up continues. Your later risks may take years to show. You can also become ill for reasons besides treatment. Researchers need patients given another treatment for a fair comparison.

The placebo resembles treatment, with none of the tested medicine inside. Comparing those groups helps separate drug harm from other illness. Stopping treatment doesn't mean a person's later health stops mattering. Without later checks, you won't know about delayed problems.

HIV had changed where the tesamorelin adults stored fat. With HIV, the immune system becomes less able to fight infection. Fat around their organs and inside their livers decreased. Their illness differs from your ordinary reasons for gaining weight.

The patients' weight excluding fat increased as well ^[1]. The measure combines muscle and bone with body water. Serious illness linked to tesamorelin wasn't reported in the review. You can't read that as saying every patient felt fine.

The CJC-1295 / ipamorelin partners still lack a trial together. Separate drugs and other combinations supplied the findings ^[17][20][21]. Their results don't establish the partners' effects on your health. CJC-1295 / ipamorelin's safety needs more than separate blood-test results.

A bottle name leaves the contents and your benefit unproved

Calling a medicine a peptide describes its makeup. Your benefit isn't proved by the word peptide. Nor does the name tell you what's inside a bottle. Germs and wrong ingredients can't be ruled out from a name.

Approval concerns the illness that your medicine was tested to treat. Tesamorelin approval concerns adults whose HIV is accompanied by unusual belly fat ^[2]. The fat being treated surrounds internal organs in those patients. Your usual weight gain isn't covered by that approval.

Sermorelin's earlier approval addressed a childhood shortage of growth hormone. That earlier use doesn't prove the adult benefits advertised now. Human treatment hasn't been approved for ipamorelin. CJC-1295 / ipamorelin also lacks approval as a human treatment.

Study results concern the actual medicine given to those patients. You can't use a paper to check another bottle's contents. A matching name doesn't prove matching medicine inside. Your health benefit and the contents both need their own proof.

The strongest adult finding was fat loss in people with HIV

Tesamorelin trials enrolled adults whose HIV had affected fat storage. Their illness may differ from your weight concern. Fat scans, sugar tests and illness checks found a benefit ^[1][3][4][5]. Less fat in those adults is the strongest benefit finding here.

Sermorelin makes your gland send more growth hormone into blood ^[6]. The studied children had too little hormone for normal growth. Those children gained height more quickly during treatment ^[10]. A doctor's review found the aging-treatment promises weren't justified ^[8].

The human ipamorelin tests followed people only briefly. Your later illness risk couldn't be settled by those short checks. Surgery patients ate sooner, but the drug's benefit wasn't clear ^[13]. Volunteers' blood tests did show a brief growth hormone increase ^[14].

The proposed CJC-1295 / Ipamorelin treatment hasn't been tested in people. Earlier tests combined other drugs and increased hormone release ^[19][21]. CJC-1295 alone kept the gland's and liver's hormone readings raised longer ^[17]. You can compare the patients and findings before weighing the promises.

Extra growth hormone may make blood sugar harder to lower

Brief follow-up leaves some of your safety questions unanswered. A report must count illness in both treatment groups. The people who quit treatment still need health checks. Otherwise, illness after they leave may go uncounted.

Your insulin lowers blood sugar; insulin is a hormone. Extra growth hormone may weaken that help from insulin. Insulin-like growth factor from your liver also encourages cells to grow. A drug review raised sugar concerns and called for longer checks ^[16].

Cancer questions need more time than brief hormone tests. Cancer may become clear years after a trial ends. You can't use one medicine's reassuring results to clear another. Your long-term risks require evidence about the drug actually used.

Rat tests found heart muscle injury with a different related medicine ^[12]. That rat experiment used a medicine other than ipamorelin. Their injury can't establish that ipamorelin damages your heart. You still need human checks of ipamorelin's own heart effects.